Eureka Therapeutics

Eureka Therapeutics

Eureka Therapeutics is a biotechnology company developing immunotherapies for the treatment of cancer

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Eureka Therapeutics Inc funding round, January 2018
60,000,000
January 2018
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Perry Liu

Employee

Vanessa Gunther

Employee

Further reading

Title
Author
Link
Type
Date

Eureka Therapeutics Announces Data Presentations Validating Its Proprietary E-ALPHA Discovery Platform at the 2018 ASH Annual Meeting

Business Wire

Web

Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor Platform for Safer T Cell Therapies

Business Wire

Web

Eureka Therapeutics Inc. and Boehringer Ingelheim Announce a Collaboration to Identify Next Generation Antibodies for Cancer Treatment

Dr Reinhard Malin

Web

Eureka Therapeutics raises $21 million in Series C to expand cancer immunotherapy pipeline

EUREKA THERAPEUTICS, INC.

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.